THE AMYLOIDOSIS FOUNDATION (EIN 200291856) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2003

Legal Domicile

Principal Officer

MARY ODONNELL

Phone

2489229610

Tax Period

2023-01-01 to 2023-12-31

THE AMYLOIDOSIS FOUNDATION, founded in 2003, is a small nonprofit in the Medical Research sector that reported $535K in total revenue in fiscal year 2023. Revenue fell 25% from the prior year — a significant decline worth monitoring.

Mission

THE ORGANIZATIONS MISSION IS TO INCREASE EDUCATION AND AWARENESS OF AMYLOIDOSIS, TO ASSIST PATIENTS IN FINDING QUALIFIED MEDICAL CARE AND TO SUPPORT RESEARCH.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $463,050

Program Service Revenue $0

Investment Income $47,362

Other Revenue $24,750

TOTAL REVENUE $535,162

Expense Breakdown

Grants Paid $180,000

Salaries & Benefits $183,772

Fundraising Expenses $75,556

Program Expenses $445,587

Other Expenses $205,148

TOTAL EXPENSES $568,920

Year-over-Year Comparison

	2023	2022	Change
Revenue	$535,162	$710,435	-0.2%
Expenses	$568,920	$598,170	0.0%
Net Income	$-33,758	$112,265	-1.3%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$62,030

Total Directors

$62,030

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARY E ODONNELL	PRESIDENT/CEO	30.00	Officer Director	$62,030	$0	$62,030
DANTE BURCHI	TREASURER	5.00	Officer Director	$0	$0	$0
MARK SUTHERLAND	CHIEF FINANCIAL OFFICER	5.00	Officer Director	$0	$0	$0
CHARLOTTE HAFFNER	DIRECTOR	5.00	Director	$0	$0	$0
ADRIENNE MOLTENI	DIRECTOR	5.00	Director	$0	$0	$0
DAN LENIHAN	DIRECTOR	5.00	Director	$0	$0	$0
LORI LAWTER	DIRECTOR	5.00	Officer Director	$0	$0	$0
STACY GOODMAN	DIRECTOR	5.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$535,162	$568,920	$1,050,511	$-33,758
2022	$710,435	$598,170	$1,056,187	$112,265
2021	$779,248	$709,491	$1,060,679	$69,757
2020	$693,866	$591,592	$951,168	$102,274

THE AMYLOIDOSIS FOUNDATION